Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001437749-23-013972
Filing Date
2023-05-11
Accepted
2023-05-11 16:56:20
Documents
71
Period of Report
2023-03-31

Document Format Files

Seq Description Document Type Size
1 FORM 10-Q navb20230331_10q.htm   iXBRL 10-Q 846456
2 EXHIBIT 31.1 ex_513860.htm EX-31.1 8653
3 EXHIBIT 31.2 ex_513861.htm EX-31.2 8652
4 EXHIBIT 32.1 ex_513862.htm EX-32.1 4491
5 EXHIBIT 32.2 ex_513863.htm EX-32.2 4400
  Complete submission text file 0001437749-23-013972.txt   5604322

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA navb-20230331.xsd EX-101.SCH 63874
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE navb-20230331_def.xml EX-101.DEF 481177
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE navb-20230331_lab.xml EX-101.LAB 382524
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE navb-20230331_pre.xml EX-101.PRE 498219
10 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE navb-20230331_cal.xml EX-101.CAL 35462
65 EXTRACTED XBRL INSTANCE DOCUMENT navb20230331_10q_htm.xml XML 653112
Mailing Address 4995 BRADENTON AVENUE SUITE 240 DUBLIN OH 43017
Business Address 4995 BRADENTON AVENUE SUITE 240 DUBLIN OH 43017 6147937500
NAVIDEA BIOPHARMACEUTICALS, INC. (Filer) CIK: 0000810509 (see all company filings)

EIN.: 311080091 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-35076 | Film No.: 23911931
SIC: 2835 In Vitro & In Vivo Diagnostic Substances